452 related articles for article (PubMed ID: 23977665)
1. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
2. Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Shirley M; McCormack PL
Drugs; 2014 Apr; 74(5):579-86. PubMed ID: 24610703
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
7. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
[TBL] [Abstract][Full Text] [Related]
8. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Wilson JM; Parker C
Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
[TBL] [Abstract][Full Text] [Related]
10. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Parker C; Zhan L; Cislo P; Reuning-Scherer J; Vogelzang NJ; Nilsson S; Sartor O; O'Sullivan JM; Coleman RE
Eur J Cancer; 2017 Jan; 71():1-6. PubMed ID: 27930924
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
[TBL] [Abstract][Full Text] [Related]
12. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
13. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
14. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
15. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
16. Practical guide to the use of radium 223 dichloride.
Den RB; Doyle LA; Knudsen KE
Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Shore ND
Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
